This is a routine post-annual-meeting filing with no earnings or operational data. The authorized share increase and equity plan approvals signal potential future dilution for equity grants or capital raises, but no immediate catalyst. Monitor for subsequent equity issuances or grant activity under the new plans.
Price Chart
Executive Summary
Palisade Bio filed an 8-K reporting its 2026 annual meeting results, including stockholder approval to increase authorized common shares from 300M to 450M, adoption of an amended equity incentive plan (42.257M shares reserved) and ESPP (837K shares reserved), and the appointment of Jordan Zwick to the board with a $566,000 RSU grant. These are routine governance and capital-structure actions that provide headroom for future equity grants but do not reflect any change in operating performance or business outlook.
Key Facts
- Authorized common shares increased from 300,000,000 to 450,000,000, effective June 11, 2026.
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan, reserving 42,257,000 shares for future awards.
- Stockholders approved the Amended and Restated 2021 Employee Stock Purchase Plan, reserving 837,000 shares.
- Board expanded from five to six directors; Jordan Zwick appointed as independent director and Audit Committee member.
- Mr. Zwick receives an initial RSU grant valued at $566,000, vesting in three equal annual installments.
- All four incumbent directors (J.D. Finley, Donald Williams, Emil Chuang, Robert F. Baltera, Jr.) were re-elected.
- Baker Tilly US, LLP ratified as independent auditor for FY2026.
- Non-binding advisory vote on executive compensation passed with 58% of votes cast in favor.
- Equity grants to non-employee directors approved by stockholders.
Financial Impact
No immediate financial impact. The authorized share increase and equity plan amendments provide capacity for future equity compensation and potential capital raises, but no issuance has occurred.
Risk Factors
- Potential future dilution from up to 42.257M new shares under the equity incentive plan and 837K under the ESPP.
- No financial results or guidance provided in this filing — business performance unknown.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028322 |
| Exhibit: ex10-3.htm | 0001493152-26-028322 |
| Exhibit: ex3-1.htm | 0001493152-26-028322 |
| Document: form8-k.htm | 0001493152-26-028322 |
| Document: 0001493152-26-028322-index-headers.html | 0001493152-26-028322 |
| Document: 0001493152-26-028322-index.html | 0001493152-26-028322 |
| Document: 0001493152-26-028322.txt | 0001493152-26-028322 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $2.14 $2.05 | ▼ −4.21% | ▼ −3.15% | $1.45 (−32.48%) |
Jul 10, 2026 11w ago | Insider Cluster | $1.89 $2.10 | ▲ +11.11% | ▲ +7.93% | $1.45 (−23.54%) |
Jul 8, 2026 12w ago | Insider Cluster | $1.97 $2.09 | ▲ +6.09% | ▲ +3.85% | $1.45 (−26.65%) |
Jun 11, 2026 16w ago | 8-K | $1.71 $1.96 | ▲ +14.62% | ▲ +12.84% | $1.45 (−15.50%) |
May 22, 2026 19w ago | EFFECT | $1.95 $1.89 | ▼ −3.08% | ▼ −1.66% | $1.45 (−25.90%) |
May 12, 2026 20w ago | S-3 | $1.87 $1.78 | ▼ −4.81% | ▼ −4.20% | $1.45 (−22.73%) |
Apr 29, 2026 22w ago | DEFA14A | $2.00 $2.12 | ▲ +6.00% | ▲ +0.77% | $1.45 (−27.75%) |
Apr 2, 2026 26w ago | 8-K | $1.89 $2.00 | ▲ +5.82% | ▼ −4.06% | $1.45 (−23.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access